Today, our screeners were at work and below is a list of 4 HealthTech Stocks up over 82% past 10 days and have been added to our watchlist. These are very volatile stocks so please do your own research before you make any investments. While we list the ratings of various 3rd party services, we're not recommending these stocks and we're not paid by the featured tickers, we simply report the big movers. If the editor has a position, it will be noted below the charts.
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Summary: Rain Therapeutics Inc. is a clinical-stage precision oncology company developing therapies which target oncogenic drivers. The company's lead product candidate includes RAIN-32. Rain Therapeutics Inc. is based in NEWARK, Calif.
Recent RAIN Stock Price (approx 10:00am EST.): $5.81
Previous Close for RAIN Stock: $4.94
Percentage Price Change Past 10 Days for RAIN stock: +150%
What is the forecast for RAIN stock? Here are 3rd party ratings for RAIN stock:
|
What’s the sentiment on the street for RAIN stock? Current ratings compiled by TipRanks.com)
|
Click for the RAIN stock Chart >>
Pricing & Percentages as of approximately 10:00am EST.
-----------------------------------------------------------------------------------------
Summary: Clovis Oncology, Inc. is a biopharmaceutical companyfocused on acquiring, developing and commercializing innovative anti-cancer agents.'Clovis has only one marketed drug in its portfolio a poly ADP-ribose polymerase inhibitor, namely Rubraca that is approved for the treatment of certain patients with ovarian and prostate cancer.'Currently, Rubraca is approved in the United States for two indications specific to ovarian cancer in the second and third or later-line setting. The drug is also approved in the United States under accelerated approval as monotherapy for treating BRCA-mutant metastatic castrate-resistant prostate cancer.'A broad development program on Rubraca is currently underway across a variety of solid tumors. Clovis is looking to expand Rubraca's label into additional cancer types like breast and gastroesophageal cancers, among others. Meanwhile, Clovis holds global development and commercialization rights to Rubraca.
Recent CLVS Stock Price (approx 10:00am EST.): $2.28
Previous Close for CLVS Stock: $1.8
Percentage Price Change Past 10 Days for CLVS stock: +101%
What is the forecast for CLVS stock? Here are 3rd party ratings for CLVS stock:
|
What’s the sentiment on the street for CLVS stock? Current ratings compiled by TipRanks.com)
|
Click for the CLVS stock Chart >>
Pricing & Percentages as of approximately 10:00am EST.
-----------------------------------------------------------------------------------------
Summary: Anebulo Pharmaceuticals Inc. is a clinical-stage biotechnology company. It involved in developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The company's product candidate includes ANEB-001. Anebulo Pharmaceuticals Inc. is based in Texas, United States.
Recent ANEB Stock Price (approx 10:00am EST.): $5.50
Previous Close for ANEB Stock: $5.2
Percentage Price Change Past 10 Days for ANEB stock: +86%
What is the forecast for ANEB stock? Here are 3rd party ratings for ANEB stock:
|
What’s the sentiment on the street for ANEB stock? Current ratings compiled by TipRanks.com)
|
Click for the ANEB stock Chart >>
Pricing & Percentages as of approximately 10:00am EST.
-----------------------------------------------------------------------------------------
HTG Molecular Diagnostics, HTGM
Summary: HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona.
Recent HTGM Stock Price (approx 10:00am EST.): $1.08
Previous Close for HTGM Stock: $1.03
Percentage Price Change Past 10 Days for HTGM stock: +82%
What is the forecast for HTGM stock? Here are 3rd party ratings for HTGM stock:
|
What’s the sentiment on the street for HTGM stock? Current ratings compiled by TipRanks.com)
|
Click for the HTGM stock Chart >>
Pricing & Percentages as of approximately 10:00am EST.
-----------------------------------------------------------------------------------------
Just a reminder, one resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
The information in this article was pulled from third part services. The prices listed above are not real-time and will be delayed at least 15 minutes.
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.